title: The use of interferon-alpha in virus infections.
abstract: The interferons (IFN) act too slowly to arrest acute viral infections, but interferon-alpha (IFN alpha) preparations have proved useful in some chronic infections and will clearly be used increasingly in these in the future. In the preparations derived from human leucocytes or cultured B lymphoblastoid cells, which are in routine clinical use, mixtures of a number of distinct subtypes of human IFN alpha have been identified. There are also 3 slightly different versions of the same single subtype, IFN alpha-2, made by recombinant DNA procedures in bacteria. IFN alpha preparations are injected intramuscularly or subcutaneously. Dose-related side effects are common but usually tolerable, but prolonged treatment may cause increasing fatigue and depression. Some patients form neutralising antibodies which block the effects of the IFN; these appear to be relatively more common after recombinant IFN alpha-2 than after IFN derived from human cells. Given intranasally, IFN alpha can prevent a subsequent experimental rhinovirus infection, or the spread of natural colds within a family. Repeated administration progressively damages the nasal mucosa, so that long term prophylaxis is not possible. IFN alpha has proved useful in patients with papillomavirus warts of the larynx, ano-genital region (condyloma acuminata) and skin (common warts). Treatment regimens remain to be optimised and are likely to include surgery or other treatments. IFN alpha and zidovudine (azidothymidine) synergistically inhibit the growth of HIV in vitro, and combination are on trial in patients with early AIDS. Very large doses of IFN alpha are effective against Kaposi's sarcoma in some AIDS patients. In chronic hepatitis B, continuing virus replication may lead to cirrhosis or primary liver cancer. Earlier clinical trials with IFN alpha gave inconclusive results, but recent large studies have confirmed that 25 to 40% of patients obtain benefit; this probably results from both the antiviral and the immunomodulatory effects of IFN alpha. In patients with chronic hepatitis C, the biochemical markers usually improve rapidly during IFN alpha administration, but relapse if treatment is stopped after only a few months; to increase the chances of sustained cure, the treatment period is now being prolonged.
authors.affiliation: Wellcome Research Laboratories, Beckenham, Kent, England.
authors.forename: N B
authors.initials: NB
authors.lastname: Finter
authors.forename: S
authors.initials: S
authors.lastname: Chapman
authors.forename: P
authors.initials: P
authors.lastname: Dowd
authors.forename: J M
authors.initials: JM
authors.lastname: Johnston
authors.forename: V
authors.initials: V
authors.lastname: Manna
authors.forename: N
authors.initials: N
authors.lastname: Sarantis
authors.forename: N
authors.initials: N
authors.lastname: Sheron
authors.forename: G
authors.initials: G
authors.lastname: Scott
authors.forename: S
authors.initials: S
authors.lastname: Phua
authors.forename: P B
authors.initials: PB
authors.lastname: Tatum
mesh_terms: D015658:HIV Infections / Q000628:therapy; D006509:Hepatitis B / Q000628:therapy; D006526:Hepatitis C / Q000628:therapy; D006801:Humans; D007370:Interferon Type I / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D027383:Papillomaviridae / Q000187:drug effects; D011994:Recombinant Proteins; D012141:Respiratory Tract Infections / Q000628:therapy; D014412:Tumor Virus Infections / Q000628:therapy; D014777:Virus Diseases / Q000628:therapy*
chemical_list: D007370:Interferon Type I; D016898:Interferon-alpha; D011994:Recombinant Proteins